The cost of treating small cell lung cancer (Q44268611)

1 December 2017

title

The cost of treating small cell lung cancer (English)

1 reference

1 December 2017

3

V. J. Gebski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:1320729

6 December 2023

author name string

M. A. Rosenthal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:1320729

6 December 2023

P. J. Webster

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:1320729

6 December 2023

R. C. Stuart-Harris

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:1320729

6 December 2023

A. O. Langlands

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:1320729

6 December 2023

J. Boyages

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:1320729

6 December 2023

language of work or name

English

0 references

publication date

1 May 1992

1 reference

1 December 2017

4 May 1992

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1320729

full work available at URL

6 December 2023

https://onlinelibrary.wiley.com/doi/pdf/10.5694/j.1326-5377.1992.tb121456.x

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Medical Journal of Australia

6 December 2023

published in

1 reference

1 December 2017

volume

156

1 reference

1 December 2017

issue

9

1 reference

1 December 2017

page(s)

605-610

1 reference

Cancer chemotherapy--the price to be paid

1 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Cost-effectiveness in oncology.

6 December 2023

2

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Dare we count the cost of cancer chemotherapy?

6 December 2023

3

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

6 December 2023

Counting costs of care

4

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Counting the costs of cancer therapy

6 December 2023

5

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

The management of oesophageal carcinoma: radiotherapy or surgery? Cost considerations

6 December 2023

6

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer

6 December 2023

7

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer

6 December 2023

8

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.

6 December 2023

10

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer

6 December 2023

11

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.

6 December 2023

12

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis

6 December 2023

13

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Quality adjusted survival analysis

6 December 2023

14

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy

6 December 2023

15

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Nonmedical costs to patients and their families associated with outpatient chemotherapy

6 December 2023

19

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer

6 December 2023

20

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research

6 December 2023

21

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

Small cell lung cancer 1973–1983: Early progress and recent obstacles

6 December 2023

22

1 reference

https://api.crossref.org/works/10.5694/J.1326-5377.1992.TB121456.X

6 December 2023

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1320729

6 December 2023

1 reference